Article Text

Download PDFPDF
▼Oxcarbazepine for epilepsy - a useful new choice?
  • Relevant BNF section: 4.8.1


▼Oxcarbazepine* (Trileptal - Novartis), an anti-epileptic first marketed in the UK in 2000, is licensed for use both as adjunctive (add-on) therapy and as monotherapy for adults and children aged 6 years or over with partial-onset epileptic seizures, with or without secondary generalisation. The company claims that oxcarbazepine has "comparable efficacy" to carbamazepine with "greater tolerability", and causes "fewer withdrawals due to side effects compared to most established antiepileptic drugs". Here we discuss the place of oxcarbazepine in the treatment of epilepsy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.